Skip to content

The HiRAD study: High-risk cohort for atopic diathesis study

The HiRAD study: High-risk cohort for atopic diathesis study - The HiRAD study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000023865
Enrollment
350
Registered
2016-09-01
Start date
2018-07-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eczema Food Allergy Asthma Allergic rhinitis

Interventions

None listed

Sponsors

Division of General Allergy, Allergy Center, National Center for Child Health and Development
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Infants whose guardians consent to this study during mid-pregnancy and who satisfy both of the following criteria: (1) born at the National Center for Child Health and Development (2) with a family history of atopic dermatitis (at least any one of parents or siblings)

Exclusion criteria

Exclusion criteria: Non-Japanese-speaking caregivers, stillbirths, any other urgent medical attention necessary

Design outcomes

Primary

MeasureTime frame
Prevalence at 6, 12, 18 months, and 2, 3, 4, 5, 6 years of age and cumulative incidence of each disease at 6 years of age: atopic dermatitis, food allergy (egg, milk), asthma, allergic rhino-conjunctivitis [Time frame: 6 years] [Designated as safety issue: No]

Secondary

MeasureTime frame
Food allergy (wheat, peanut, and others) Asthma severity Total IgE, allergen specific IgEs, TARC/CCL17 Allergen specific IgG4s, affinity of OVA-/OVM-specific IgE Microbiome profiles (skin, gut) EASI (Eczema Area and Severity Index) POEM (Patient Oriented Eczema Measure)

Countries

Japan

Contacts

Public ContactTatsuki Fukuie

National Center for Child Health and Development Division of General Allergy, Allergy Center

fukuie-t@ncchd.go.jp03-3416-0611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026